


# Heparin-induced Thrombocytopenia: Laboratory Diagnosis

Andreas Greinacher

Institut für Immunologie und Transfusionsmedizin

Ernst-Moritz-Arndt-Universität Greifswald

Leiden, November 2008




# Heparin-Platelet Interactions

- (Non immune heparin-associated thrombocytopenia (HIT type I))
- **Immune-mediated heparin-induced thrombocytopenia (HIT type II)**


**= HIT**

**clinico-pathological syndrome  
(clinical symptoms + antibodies)**

# Heparin-induced thrombocytopenia a link between immune system and hemostasis



Lys + Arg



# Clinical features of HIT

**Platelet count decrease > 50%  
and/or  
new thrombotic complications  
between day 5-14 of heparin**

# Diagnosis - pretest probability: the 4 T's

	2	1	0
A <b>Thrombocytopenia</b>	> 50% platelet count fall to nadir $\geq$ 20	30-50% platelet count fall to nadir 10-19	<30% platelet count fall to nadir $\leq$ 10
B <b>Timing of fall in platelet count or other sequelae</b>	Onset d 5-10 or < 1 d (if heparin exposure within 30 d)	> d 10, or timing unclear, or < d 1 with recent heparin 31-100 d	Platelet count fall < d 4 (without recent heparin exposure)
C <b>Thrombosis or other sequelae</b>	New thrombosis; skin necrosis; post-heparin bolus acute systemic reaction	Progressive or recurrent thrombosis; erythematous skin lesions; suspected thrombosis – not confirmed	None
D <b>Other cause for thrombocytopenia</b>	No other cause for platelet count fall is evident	Possible other cause is evident	Definite other cause is present

# Diagnosis - pretest probability

## Interpretation of 4 T's score

**Score 0 - 3:** very unlikely to be HIT (<5%)

Lo et al. J Thromb Haemost 2006

# Laboratory Tests for HIT antibodies


- Antigen tests
  - rPF4/heparin IgG/M/A (Stago)
  - PF4/polyvinylsulfonate IgG/M/A, IgG (GTI)
  - Heparin/platelet lysate (HIA; Hyphen)
  - PF4/heparin IgG, IgA, IgM (Greifswald)
  - (Fluid phase ELISA)
  - Microcolumn IgG/A/M (Diamed)
  - PIFA rapid test
- Functional assays
  - Platelet aggregation using PRP
  - Platelet activation using washed platelets
    - Optical assessment heparin induced platelet activation (HIPA) test
    - Serotonin release: <sup>14</sup>C serotonin release (SRA), HPLC, ELISA
    - Flow cytometry: microparticles, annexin V
  - miscellaneous



**Antigen test**  
PF4/heparin ELISA  
microcolumn

**Functional test**  
HIPA-test  
 $^{14}\text{C}$ -SRA


**Sonography**




# PF4/heparin Antigen Tests





- + Detect IgG, IgA, and IgM antibodies
- + Somewhat standardized
- Detect only PF4 dependent antigens
- Control of sensitivity/specificity of different lots??




## Zymotest HIA




+/-  
Platelet  
or Leucocytes lysates



+ additionally detects anti IL8 antibodies




# Immuno Beads Assay PaGIA (Diamed)




= PF4/heparin coated beads

 = human antibody


 = anti-human Ig



negative



positive



Modified from Warkentin TE, in HIT, Warkentin and Greinacher 2007

# How to improve specificity of antigen tests?

Test for anti-PF4/heparin IgG.

IgM and IgA antibodies are of minor relevance

Greinacher et al JTH 2007;5:1666-73


# How to improve specificity of antigen tests?

Use a higher cut off.  $OD > 1.0$  is more likely to be of clinical relevance than an  $OD < 1.0$

Zwicker et al JTH 2004;2:2133-7

- few functionally very active antibodies show an  $OD < 1.0$

# EIA-SRA Relationship: GTI Assay (n=405)





# PaGIA Microcolumn Test

Serial dilution of positive sera (2-fold steps)

- Clinically unlikely HIT:
  - titers  $\geq 4$ : 2/85 (2%)
- Clinically probable or highly probable HIT:
  - titers  $\geq 4$ : 39/54 (72%)
- Thrombosis:
  - negative or titer  $< 4$ : 8%
  - titer 4–16: 55%
  - titer  $\geq 32$ : 74%

# How to improve specificity of antigen tests?

Add a confirmatory step with high heparin to show specificity for PF4/heparin complexes



Whitlatch et al. Thromb Haemost 2008;100;678-84

- especially high affinity binding HIT antibodies may not be inhibitable, valid for ODs < 1.0

# PIFA Heparin/PF4 Rapid Assay



Do NOT use this assay totally random results = non-informative assay JTH 2007



# Functional assays for HIT

- Require fresh platelets
- Washing is critical
- Internal controls are important
- Require experienced staff
- Time consuming
- Not available as test kit

# Platelet aggregation test


120  $\mu$ l PRP

75  $\mu$ l heat inactivated serum



10  $\mu$ l heparin/buffer

- + Relatively easy to perform
- + Antigen independent
- Low sensitivity
- False positive reactions

# HIPA test




# <sup>14</sup>C SRA





- + 10 µl heparin
- 0.2 U f.c or 100 U f.c.
- **high heparin:** heparin dependency;
- **hirudin:** eliminates thrombin effects;
- **moab IV.3:** Fc-RIIa dependency



# SRA is a “Dichotomizing” Assay



# Generation of microparticles



# Binding of Annexin V






# Frequency of HIT in Patients Suspected to Have HIT

- Reference laboratory experience
- Consecutive patients referred with clinical suspicion of HIT: 2405
- Positive antigen test: 309 (12.8%)
- Positive functional assay: 151 (6.3%)

**> 90% of patients did not have HIT**

**Antigen test**  
PF4/heparin ELISA  
Microcolumn  
IgG/A/M


**Functional test**  
HIPA-test  
 $^{14}\text{C}$ -SRA  
IgG/ other antigens




# Frequency of “HIT”: Platelet Fall >30% and/or Thrombosis (Pos HIPA test)

	UFH	LMWH*	
HIT-T	6/231 ( <b>2.6%</b> )	0/271 ( <b>0.0%</b> )	$P < 0.0092$
HIT	12/231 ( <b>5.2%</b> )	0/271 ( <b>0.0%</b> )	$P = 0.00008$
HIPA	25/202 ( <b>12.4%</b> )	13/238 ( <b>5.5%</b> )	$P = 0.0101$
EIA	46/196 ( <b>23.5%</b> )	19/228 ( <b>8.3%</b> )	$P = 0.00002$

\* Enoxaparin





# Cardiac Surgery Unfractionated Heparin



# A Practical Approach

- Do not screen for PF4/heparin antibodies
- Include the 4T score in the clinical assessment
- HIT antibody test:
  - for exclusion of HIT use antigen test with high negative predictive value
  - for confirmation of HIT use functional test with high positive predictive value





# The Greifswald Approach

- PF4/heparin EIA IgG + high heparin control  
(IgA and IgM only to explain a positive result in an external laboratory)
- HIPA test with platelets of 4 donors
- Same day results (Mo-Fr)
- Charging: 100 €



**P. Eichler**  
**N. Lubenow**  
**K. Selleng**  
**S. Selleng**  
**D. Juhl**  
**C. Blumentritt**  
**U. Strobel**  
**B. Fürll**  
**T. Lietz**  
**S. Schenk**  
  
**T.E. Warkentin**



*Universitätsklinikum Greifswald*

University Hospital Greifswald

